Related Experiment Videos

Human developmental toxicity and mutagenesis

H S Rosenkranz1, Y P Zhang, O T Macina

  • 1Department of Environmental and Occupational Health University of Pittsburgh, Pittsburgh, PA 15238, USA.rsnkranz@vms.cis.pitt.edu

Mutation Research
|December 5, 1998
PubMed

Insights

This study analyzed a human developmental toxicity model, finding mechanistic links to other toxicities but surprisingly no overlap with Salmonella mutagenicity due to pre-screening methods.

Area of Science:

  • Toxicology
  • Drug Development
  • Mechanistic Toxicology

Background:

  • Structure-Activity Relationship (SAR) models are crucial for predicting chemical toxicity.
  • Human developmental toxicity is a complex endpoint with multiple potential molecular targets.
  • Previous SAR models have shown overlaps across various toxicological phenomena.

Purpose of the Study:

  • To further analyze a SAR model for human developmental toxicity.
  • To investigate mechanistic similarities and differences with other toxicological endpoints.
  • To understand the relationship between developmental toxicity and mutagenicity.

Main Methods:

  • Analysis of an existing SAR model for human developmental toxicity.
  • Comparative analysis of mechanistic similarities with SAR models for systemic toxicity, chromosomal, and genomic effects.
  • Comparative analysis of mechanistic overlap with mutagenicity in Salmonella.

Main Results:

  • The developmental toxicity SAR model shares mechanistic similarities with models for systemic toxicity, chromosomal, and genomic effects.
  • There was a surprising lack of significant mechanistic overlap between human developmental toxicity and Salmonella mutagenicity.
  • This lack of overlap is potentially explained by pre-screening strategies eliminating Salmonella mutagens from therapeutics.

Conclusions:

  • Human developmental toxicity involves multiple targets, sharing mechanistic pathways with other toxicological effects.
  • The Ames test (Salmonella mutagenicity assay) may not adequately capture developmental toxicants due to drug pre-screening.
  • Further refinement of predictive toxicology models is needed to account for specific toxicological endpoints and drug development pipelines.

Related Concept Videos